Literature DB >> 10721956

Subretinal surgery for choroidal neovascularization in patients with high myopia.

A Uemura1, M A Thomas.   

Abstract

OBJECTIVE: To analyze the visual outcome in patients undergoing surgical removal of subfoveal choroidal neovascularization (CNV) in eyes with high myopia.
METHODS: We retrospectively reviewed the medical records of 48 consecutive patients with high myopia (> or =6 diopters [D]) who underwent vitrectomy with surgical removal of subfoveal CNV. The patient population consisted of 2 groups. Group 1 included 23 patients with findings only of myopic degeneration, and group 2 included 25 patients with presumed ocular histoplasmosis syndrome and myopia of 6 D or more.
RESULTS: In group 1, the visual acuity improved by 2 or more Snellen lines in 9 eyes (39%), decreased in 8 eyes (35%), and remained unchanged in 6 (26%), with a mean follow-up of 24 months (range, 8-60 months). The preoperative visual acuity was 20/40 or better in only 1 eye (4%), but 8 (35%) achieved a final visual acuity of 20/40 or better. In group 2, the visual acuity improved in 16 eyes (64%), was stable in 4 (16%), and deteriorated in 5 (20%), with a mean follow-up of 18 months (range, 6-44 months). Only 3 eyes (12%) had a preoperative visual acuity of 20/40 or better, but 11 (44%) achieved a final visual acuity of 20/40 or better. Recurrence occurred in 13 (57%) of the 23 eyes in group 1 and in 9 (36%) of the 25 eyes in group 2. Univariate analysis demonstrated a significant relation between younger patient age (group 1) and absence of postoperative CNV recurrence (group 2) and an improvement of visual acuity (P<.01).
CONCLUSIONS: Surgical removal of CNV may provide visual benefit in selected cases of subfoveal CNV associated with high myopia. The determination of whether surgical intervention is appropriate in these cases requires a prospective, randomized, clinical trial.

Entities:  

Mesh:

Year:  2000        PMID: 10721956     DOI: 10.1001/archopht.118.3.344

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  10 in total

1.  Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients.

Authors:  J M Ruiz-Moreno; C de la Vega
Journal:  Br J Ophthalmol       Date:  2001-09       Impact factor: 4.638

2.  Outcome of photodynamic therapy in choroidal neovascularization due to pathologic myopia and related factors.

Authors:  Tugrul Altan; Nur Acar; Ziya Kapran; Yaprak B Unver; Sezin Ozdogan
Journal:  Int Ophthalmol       Date:  2012-02-19       Impact factor: 2.031

Review 3.  Choroidal neovascularisation in pathological myopia: an update in management.

Authors:  W-M Chan; M Ohji; T Y Y Lai; D T L Liu; Y Tano; D S C Lam
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

4.  Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia.

Authors:  Izumi Yamamoto; Adam H Rogers; Elias Reichel; Paul A Yates; Jay S Duker
Journal:  Br J Ophthalmol       Date:  2006-07-26       Impact factor: 4.638

Review 5.  Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.

Authors:  Ying Zhu; Ting Zhang; Gezhi Xu; Lijun Peng
Journal:  Cochrane Database Syst Rev       Date:  2016-12-15

6.  Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses.

Authors:  Jose M Ruiz-Moreno; Javier A Montero; Pedro Amat-Peral
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-01-14       Impact factor: 3.117

Review 7.  Recent trends in the management of maculopathy secondary to pathological myopia.

Authors:  D Mitry; H Zambarakji
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-13       Impact factor: 3.117

8.  Surgical removal of subfoveal choroidal neovascularization in pathologic myopia: a 12-year follow-up study.

Authors:  R Hera; C Chiquet; J P Romanet
Journal:  Int Ophthalmol       Date:  2013-03-29       Impact factor: 2.031

Review 9.  Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy.

Authors:  Kelvin Yi Chong Teo; Wei Yan Ng; Shu Yen Lee; Chui Ming Gemmy Cheung
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

10.  Genetic Polymorphisms in VEGFR Coding Genes (FLT1/KDR) on Ranibizumab Response in High Myopia and Choroidal Neovascularization Patients.

Authors:  David Blánquez-Martínez; Xando Díaz-Villamarín; Sonia García-Rodríguez; Alba Antúnez-Rodríguez; Ana Pozo-Agundo; Luis Javier Martínez-González; José Ignacio Muñoz-Ávila; Cristina Lucía Dávila-Fajardo
Journal:  Pharmaceutics       Date:  2022-07-26       Impact factor: 6.525

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.